PURPOSE: Treatment with (131)I-MIBG is associated with significant thyroid damage. This study was undertaken to investigate the long-term efficacy of current thyroid prophylaxis, to explore the relationship between thyroid dysfunction and thyroid volume after exposure to (131)I-MIBG and to evaluate the possible negative effects of (131)I(-) on the parathyroid glands. METHODS: Of 81 long-term surviving patients with neuroblastoma treated with (131)I-MIBG during the period 1999-2012, 24 were finally evaluated. Patients received thyroxine (T4), methimazole and potassium iodide as thyroid protection. In all patients (para)thyroid function was evaluated and ultrasound investigation of the (para)thyroid gland(s) was performed. Thyroid dysfunction was defined as a plasma thyrotropin concentration >5.0 mU/L (thyrotropin elevation, TE) or as the use of T4 at the time of follow-up. Hyperparathyroidism was defined as a serum calcium concentration above the age-related reference range in combination with an inappropriately high parathyroid hormone level. RESULTS: At a median follow-up of 9.0 years after (131)I-MIBG treatment, thyroid disorders were seen in 12 patients (50 %; 9 with TE, 5 with a thyroid nodule and 1 patient was subsequently diagnosed with differentiated thyroid carcinoma). No significant risk factors for the occurrence of thyroid damage could be identified. In 14 of 21 patients (67 %) in whom thyroid volume could be determined, the volume was considered small (<-2SD) for age and gender. Patients treated with T4 at the time of follow-up had significantly smaller thyroid volumes for age than patients without T4 treatment (p = 0.014). None of the patients was diagnosed with hyperparathyroidism. CONCLUSION: Thyroid protection during treatment with (131)I-MIBG needs attention and must be further improved, as thyroid disorders are still frequently seen despite current thyroid prophylaxis. Reduced thyroid volume in neuroblastoma survivors may be related to previous (131)I-MIBG therapy or current T4 treatment. No deleterious effects of (131)I-MIBG on the parathyroid glands could be found.
PURPOSE: Treatment with (131)I-MIBG is associated with significant thyroid damage. This study was undertaken to investigate the long-term efficacy of current thyroid prophylaxis, to explore the relationship between thyroid dysfunction and thyroid volume after exposure to (131)I-MIBG and to evaluate the possible negative effects of (131)I(-) on the parathyroid glands. METHODS: Of 81 long-term surviving patients with neuroblastoma treated with (131)I-MIBG during the period 1999-2012, 24 were finally evaluated. Patients received thyroxine (T4), methimazole and potassium iodide as thyroid protection. In all patients (para)thyroid function was evaluated and ultrasound investigation of the (para)thyroid gland(s) was performed. Thyroid dysfunction was defined as a plasma thyrotropin concentration >5.0 mU/L (thyrotropin elevation, TE) or as the use of T4 at the time of follow-up. Hyperparathyroidism was defined as a serum calcium concentration above the age-related reference range in combination with an inappropriately high parathyroid hormone level. RESULTS: At a median follow-up of 9.0 years after (131)I-MIBG treatment, thyroid disorders were seen in 12 patients (50 %; 9 with TE, 5 with a thyroid nodule and 1 patient was subsequently diagnosed with differentiated thyroid carcinoma). No significant risk factors for the occurrence of thyroid damage could be identified. In 14 of 21 patients (67 %) in whom thyroid volume could be determined, the volume was considered small (<-2SD) for age and gender. Patients treated with T4 at the time of follow-up had significantly smaller thyroid volumes for age than patients without T4 treatment (p = 0.014). None of the patients was diagnosed with hyperparathyroidism. CONCLUSION: Thyroid protection during treatment with (131)I-MIBG needs attention and must be further improved, as thyroid disorders are still frequently seen despite current thyroid prophylaxis. Reduced thyroid volume in neuroblastoma survivors may be related to previous (131)I-MIBG therapy or current T4 treatment. No deleterious effects of (131)I-MIBG on the parathyroid glands could be found.
Authors: Parveen Bhatti; Lene H S Veiga; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Debra L Friedman; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Leslie L Robison; Peter D Inskip Journal: Radiat Res Date: 2010-10-06 Impact factor: 2.841
Authors: Rani E George; Shuli Li; Cheryl Medeiros-Nancarrow; Donna Neuberg; Karen Marcus; Robert C Shamberger; Michael Pulsipher; Stephan A Grupp; Lisa Diller Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: S C Clement; B L F van Eck-Smit; A S P van Trotsenburg; L C M Kremer; G A M Tytgat; H M van Santen Journal: Pediatr Blood Cancer Date: 2013-07-06 Impact factor: 3.167
Authors: Alekist Quach; Lingyun Ji; Vikash Mishra; Aimee Sznewajs; Janet Veatch; John Huberty; Benjamin Franc; Richard Sposto; Susan Groshen; Denice Wei; Paul Fitzgerald; John M Maris; Gregory Yanik; Randall A Hawkins; Judith G Villablanca; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2010-09-09 Impact factor: 3.167
Authors: Hanneke M van Santen; Godelieve A M Tytgat; Marianne D van de Wetering; Berthe L F van Eck-Smit; Saskia M J Hopman; Alida F van der Steeg; Els J M Nieveen van Dijkum; A S Paul van Trotsenburg Journal: Thyroid Date: 2012-04-23 Impact factor: 6.568
Authors: Lene H S Veiga; Parveen Bhatti; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Debra L Friedman; Leslie L Robison; Peter D Inskip Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10-25 Impact factor: 4.254
Authors: Allan F Moore; Tamara L Wexler; Rachel L Yung; Joshua Kish; Mykol Larvie; Kelly Lauter; Andrew Arnold; Joel S Finkelstein; Sherri M Burnett-Bowie Journal: Endocr Pract Date: 2008-10 Impact factor: 3.443
Authors: Carmen L Wilson; Kirsten K Ness; Joseph P Neglia; Sue Hammond; Margarett Shnorhavorian; Wendy L Leisenring; Marilyn Stovall; Leslie L Robison; Gregory T Armstrong Journal: J Natl Cancer Inst Date: 2013-03-20 Impact factor: 13.506
Authors: Sarah C Clement; Godelieve A M Tytgat; A S Paul van Trotsenburg; Leontien C M Kremer; Hanneke M van Santen Journal: Ann Nucl Med Date: 2022-05-02 Impact factor: 2.258
Authors: Marek Ussowicz; Aleksandra Wieczorek; Agnieszka Dłużniewska; Anna Pieczonka; Robert Dębski; Katarzyna Drabko; Jolanta Goździk; Walentyna Balwierz; Daria Handkiewicz-Junak; Jacek Wachowiak Journal: Front Oncol Date: 2021-04-12 Impact factor: 6.244
Authors: Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze Journal: Endocr Relat Cancer Date: 2022-09-07 Impact factor: 5.900